Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–crit...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-06, Vol.384 (23), p.2187-2201 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2201 |
|---|---|
| container_issue | 23 |
| container_start_page | 2187 |
| container_title | The New England journal of medicine |
| container_volume | 384 |
| creator | Sadoff, Jerald Gray, Glenda Vandebosch, An Cárdenas, Vicky Shukarev, Georgi Grinsztejn, Beatriz Goepfert, Paul A Truyers, Carla Fennema, Hein Spiessens, Bart Offergeld, Kim Scheper, Gert Taylor, Kimberly L Robb, Merlin L Treanor, John Barouch, Dan H Stoddard, Jeffrey Ryser, Martin F Marovich, Mary A Neuzil, Kathleen M Corey, Lawrence Cauwenberghs, Nancy Tanner, Tamzin Hardt, Karin Ruiz-Guiñazú, Javier Le Gars, Mathieu Schuitemaker, Hanneke Van Hoof, Johan Struyf, Frank Douoguih, Macaya |
| description | Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–critical Covid-19 and 85% against severe–critical Covid-19. Efficacy against the variant first identified in South Africa was 64% against moderate disease and 82% against severe–critical disease. |
| doi_str_mv | 10.1056/NEJMoa2101544 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8220996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2539546944</sourcerecordid><originalsourceid>FETCH-LOGICAL-c627t-33dcea7041f79fb9e77e015dd93035b03d77055b584046482372505c8874002f3</originalsourceid><addsrcrecordid>eNp1kM1PwjAYhxujEfw4ejVNjMdhP9f1YkImogblgHJtuq3FEbbiOkj4760BiRzs5T30yfP-3h8AVxj1MOLx3dvg5dVpghHmjB2BLuaURoyh-Bh0ESJJxISkHXDm_RyFh5k8BR1Kk4QQwrtgONHWtBuo6wIOrC1znW-gs3BS1rOFiR6cN7BfkLiXjqekN4FTnedlbaCe6bL2LUzduiwiLC_AidULby538xx8PA7e06doNB4-p_1RlMdEtBGlRW60QAxbIW0mjRAmJC8KSRHlGaKFEIjzjCcMsZglhArCEc-TRLBwjaXn4H7rXa6yygRZ3TZ6oZZNWelmo5wu1eFPXX6qmVurcC-SMg6Cm52gcV8r41s1d6umDpkV4VRyFkvGAhVtqbxx3jfG7jdgpH56Vwe9B_76b6w9_Vt0AG63QFV5VZt59Y_oG55jhZA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2539546944</pqid></control><display><type>article</type><title>Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Sadoff, Jerald ; Gray, Glenda ; Vandebosch, An ; Cárdenas, Vicky ; Shukarev, Georgi ; Grinsztejn, Beatriz ; Goepfert, Paul A ; Truyers, Carla ; Fennema, Hein ; Spiessens, Bart ; Offergeld, Kim ; Scheper, Gert ; Taylor, Kimberly L ; Robb, Merlin L ; Treanor, John ; Barouch, Dan H ; Stoddard, Jeffrey ; Ryser, Martin F ; Marovich, Mary A ; Neuzil, Kathleen M ; Corey, Lawrence ; Cauwenberghs, Nancy ; Tanner, Tamzin ; Hardt, Karin ; Ruiz-Guiñazú, Javier ; Le Gars, Mathieu ; Schuitemaker, Hanneke ; Van Hoof, Johan ; Struyf, Frank ; Douoguih, Macaya</creator><creatorcontrib>Sadoff, Jerald ; Gray, Glenda ; Vandebosch, An ; Cárdenas, Vicky ; Shukarev, Georgi ; Grinsztejn, Beatriz ; Goepfert, Paul A ; Truyers, Carla ; Fennema, Hein ; Spiessens, Bart ; Offergeld, Kim ; Scheper, Gert ; Taylor, Kimberly L ; Robb, Merlin L ; Treanor, John ; Barouch, Dan H ; Stoddard, Jeffrey ; Ryser, Martin F ; Marovich, Mary A ; Neuzil, Kathleen M ; Corey, Lawrence ; Cauwenberghs, Nancy ; Tanner, Tamzin ; Hardt, Karin ; Ruiz-Guiñazú, Javier ; Le Gars, Mathieu ; Schuitemaker, Hanneke ; Van Hoof, Johan ; Struyf, Frank ; Douoguih, Macaya ; ENSEMBLE Study Group</creatorcontrib><description>Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–critical Covid-19 and 85% against severe–critical Covid-19. Efficacy against the variant first identified in South Africa was 64% against moderate disease and 82% against severe–critical disease.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2101544</identifier><identifier>PMID: 33882225</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Ad26COVS1 ; Adolescent ; Adult ; Adverse events ; Age ; Aged ; Asymptomatic Diseases - epidemiology ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - mortality ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - administration & dosage ; COVID-19 Vaccines - adverse effects ; COVID-19 Vaccines - immunology ; Disease transmission ; Double-Blind Method ; FDA approval ; Female ; Hospitalization - statistics & numerical data ; Humans ; Hypotheses ; Immunogenicity, Vaccine ; Incidence ; Infections ; Male ; Middle Aged ; Original ; Pandemics ; Patient Acuity ; Placebos ; Population ; Proportional Hazards Models ; Protein structure ; Protocol ; R&D ; Research & development ; Safety ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Vaccine efficacy ; Vaccines ; Young Adult</subject><ispartof>The New England journal of medicine, 2021-06, Vol.384 (23), p.2187-2201</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2021 Massachusetts Medical Society.</rights><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c627t-33dcea7041f79fb9e77e015dd93035b03d77055b584046482372505c8874002f3</citedby><cites>FETCH-LOGICAL-c627t-33dcea7041f79fb9e77e015dd93035b03d77055b584046482372505c8874002f3</cites><orcidid>0000-0002-2179-2436 ; 0000-0001-8563-2266 ; 0000-0003-4649-1477 ; 0000-0001-9988-0260</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2101544$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2539546944?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,777,781,882,2746,2747,26084,27905,27906,52363,54045,64364,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33882225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sadoff, Jerald</creatorcontrib><creatorcontrib>Gray, Glenda</creatorcontrib><creatorcontrib>Vandebosch, An</creatorcontrib><creatorcontrib>Cárdenas, Vicky</creatorcontrib><creatorcontrib>Shukarev, Georgi</creatorcontrib><creatorcontrib>Grinsztejn, Beatriz</creatorcontrib><creatorcontrib>Goepfert, Paul A</creatorcontrib><creatorcontrib>Truyers, Carla</creatorcontrib><creatorcontrib>Fennema, Hein</creatorcontrib><creatorcontrib>Spiessens, Bart</creatorcontrib><creatorcontrib>Offergeld, Kim</creatorcontrib><creatorcontrib>Scheper, Gert</creatorcontrib><creatorcontrib>Taylor, Kimberly L</creatorcontrib><creatorcontrib>Robb, Merlin L</creatorcontrib><creatorcontrib>Treanor, John</creatorcontrib><creatorcontrib>Barouch, Dan H</creatorcontrib><creatorcontrib>Stoddard, Jeffrey</creatorcontrib><creatorcontrib>Ryser, Martin F</creatorcontrib><creatorcontrib>Marovich, Mary A</creatorcontrib><creatorcontrib>Neuzil, Kathleen M</creatorcontrib><creatorcontrib>Corey, Lawrence</creatorcontrib><creatorcontrib>Cauwenberghs, Nancy</creatorcontrib><creatorcontrib>Tanner, Tamzin</creatorcontrib><creatorcontrib>Hardt, Karin</creatorcontrib><creatorcontrib>Ruiz-Guiñazú, Javier</creatorcontrib><creatorcontrib>Le Gars, Mathieu</creatorcontrib><creatorcontrib>Schuitemaker, Hanneke</creatorcontrib><creatorcontrib>Van Hoof, Johan</creatorcontrib><creatorcontrib>Struyf, Frank</creatorcontrib><creatorcontrib>Douoguih, Macaya</creatorcontrib><creatorcontrib>ENSEMBLE Study Group</creatorcontrib><title>Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–critical Covid-19 and 85% against severe–critical Covid-19. Efficacy against the variant first identified in South Africa was 64% against moderate disease and 82% against severe–critical disease.</description><subject>Ad26COVS1</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adverse events</subject><subject>Age</subject><subject>Aged</subject><subject>Asymptomatic Diseases - epidemiology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - mortality</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - administration & dosage</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Disease transmission</subject><subject>Double-Blind Method</subject><subject>FDA approval</subject><subject>Female</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Immunogenicity, Vaccine</subject><subject>Incidence</subject><subject>Infections</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Pandemics</subject><subject>Patient Acuity</subject><subject>Placebos</subject><subject>Population</subject><subject>Proportional Hazards Models</subject><subject>Protein structure</subject><subject>Protocol</subject><subject>R&D</subject><subject>Research & development</subject><subject>Safety</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike protein</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Young Adult</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kM1PwjAYhxujEfw4ejVNjMdhP9f1YkImogblgHJtuq3FEbbiOkj4760BiRzs5T30yfP-3h8AVxj1MOLx3dvg5dVpghHmjB2BLuaURoyh-Bh0ESJJxISkHXDm_RyFh5k8BR1Kk4QQwrtgONHWtBuo6wIOrC1znW-gs3BS1rOFiR6cN7BfkLiXjqekN4FTnedlbaCe6bL2LUzduiwiLC_AidULby538xx8PA7e06doNB4-p_1RlMdEtBGlRW60QAxbIW0mjRAmJC8KSRHlGaKFEIjzjCcMsZglhArCEc-TRLBwjaXn4H7rXa6yygRZ3TZ6oZZNWelmo5wu1eFPXX6qmVurcC-SMg6Cm52gcV8r41s1d6umDpkV4VRyFkvGAhVtqbxx3jfG7jdgpH56Vwe9B_76b6w9_Vt0AG63QFV5VZt59Y_oG55jhZA</recordid><startdate>20210610</startdate><enddate>20210610</enddate><creator>Sadoff, Jerald</creator><creator>Gray, Glenda</creator><creator>Vandebosch, An</creator><creator>Cárdenas, Vicky</creator><creator>Shukarev, Georgi</creator><creator>Grinsztejn, Beatriz</creator><creator>Goepfert, Paul A</creator><creator>Truyers, Carla</creator><creator>Fennema, Hein</creator><creator>Spiessens, Bart</creator><creator>Offergeld, Kim</creator><creator>Scheper, Gert</creator><creator>Taylor, Kimberly L</creator><creator>Robb, Merlin L</creator><creator>Treanor, John</creator><creator>Barouch, Dan H</creator><creator>Stoddard, Jeffrey</creator><creator>Ryser, Martin F</creator><creator>Marovich, Mary A</creator><creator>Neuzil, Kathleen M</creator><creator>Corey, Lawrence</creator><creator>Cauwenberghs, Nancy</creator><creator>Tanner, Tamzin</creator><creator>Hardt, Karin</creator><creator>Ruiz-Guiñazú, Javier</creator><creator>Le Gars, Mathieu</creator><creator>Schuitemaker, Hanneke</creator><creator>Van Hoof, Johan</creator><creator>Struyf, Frank</creator><creator>Douoguih, Macaya</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2179-2436</orcidid><orcidid>https://orcid.org/0000-0001-8563-2266</orcidid><orcidid>https://orcid.org/0000-0003-4649-1477</orcidid><orcidid>https://orcid.org/0000-0001-9988-0260</orcidid></search><sort><creationdate>20210610</creationdate><title>Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19</title><author>Sadoff, Jerald ; Gray, Glenda ; Vandebosch, An ; Cárdenas, Vicky ; Shukarev, Georgi ; Grinsztejn, Beatriz ; Goepfert, Paul A ; Truyers, Carla ; Fennema, Hein ; Spiessens, Bart ; Offergeld, Kim ; Scheper, Gert ; Taylor, Kimberly L ; Robb, Merlin L ; Treanor, John ; Barouch, Dan H ; Stoddard, Jeffrey ; Ryser, Martin F ; Marovich, Mary A ; Neuzil, Kathleen M ; Corey, Lawrence ; Cauwenberghs, Nancy ; Tanner, Tamzin ; Hardt, Karin ; Ruiz-Guiñazú, Javier ; Le Gars, Mathieu ; Schuitemaker, Hanneke ; Van Hoof, Johan ; Struyf, Frank ; Douoguih, Macaya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c627t-33dcea7041f79fb9e77e015dd93035b03d77055b584046482372505c8874002f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Ad26COVS1</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adverse events</topic><topic>Age</topic><topic>Aged</topic><topic>Asymptomatic Diseases - epidemiology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - mortality</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - administration & dosage</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Disease transmission</topic><topic>Double-Blind Method</topic><topic>FDA approval</topic><topic>Female</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Immunogenicity, Vaccine</topic><topic>Incidence</topic><topic>Infections</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Pandemics</topic><topic>Patient Acuity</topic><topic>Placebos</topic><topic>Population</topic><topic>Proportional Hazards Models</topic><topic>Protein structure</topic><topic>Protocol</topic><topic>R&D</topic><topic>Research & development</topic><topic>Safety</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike protein</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sadoff, Jerald</creatorcontrib><creatorcontrib>Gray, Glenda</creatorcontrib><creatorcontrib>Vandebosch, An</creatorcontrib><creatorcontrib>Cárdenas, Vicky</creatorcontrib><creatorcontrib>Shukarev, Georgi</creatorcontrib><creatorcontrib>Grinsztejn, Beatriz</creatorcontrib><creatorcontrib>Goepfert, Paul A</creatorcontrib><creatorcontrib>Truyers, Carla</creatorcontrib><creatorcontrib>Fennema, Hein</creatorcontrib><creatorcontrib>Spiessens, Bart</creatorcontrib><creatorcontrib>Offergeld, Kim</creatorcontrib><creatorcontrib>Scheper, Gert</creatorcontrib><creatorcontrib>Taylor, Kimberly L</creatorcontrib><creatorcontrib>Robb, Merlin L</creatorcontrib><creatorcontrib>Treanor, John</creatorcontrib><creatorcontrib>Barouch, Dan H</creatorcontrib><creatorcontrib>Stoddard, Jeffrey</creatorcontrib><creatorcontrib>Ryser, Martin F</creatorcontrib><creatorcontrib>Marovich, Mary A</creatorcontrib><creatorcontrib>Neuzil, Kathleen M</creatorcontrib><creatorcontrib>Corey, Lawrence</creatorcontrib><creatorcontrib>Cauwenberghs, Nancy</creatorcontrib><creatorcontrib>Tanner, Tamzin</creatorcontrib><creatorcontrib>Hardt, Karin</creatorcontrib><creatorcontrib>Ruiz-Guiñazú, Javier</creatorcontrib><creatorcontrib>Le Gars, Mathieu</creatorcontrib><creatorcontrib>Schuitemaker, Hanneke</creatorcontrib><creatorcontrib>Van Hoof, Johan</creatorcontrib><creatorcontrib>Struyf, Frank</creatorcontrib><creatorcontrib>Douoguih, Macaya</creatorcontrib><creatorcontrib>ENSEMBLE Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sadoff, Jerald</au><au>Gray, Glenda</au><au>Vandebosch, An</au><au>Cárdenas, Vicky</au><au>Shukarev, Georgi</au><au>Grinsztejn, Beatriz</au><au>Goepfert, Paul A</au><au>Truyers, Carla</au><au>Fennema, Hein</au><au>Spiessens, Bart</au><au>Offergeld, Kim</au><au>Scheper, Gert</au><au>Taylor, Kimberly L</au><au>Robb, Merlin L</au><au>Treanor, John</au><au>Barouch, Dan H</au><au>Stoddard, Jeffrey</au><au>Ryser, Martin F</au><au>Marovich, Mary A</au><au>Neuzil, Kathleen M</au><au>Corey, Lawrence</au><au>Cauwenberghs, Nancy</au><au>Tanner, Tamzin</au><au>Hardt, Karin</au><au>Ruiz-Guiñazú, Javier</au><au>Le Gars, Mathieu</au><au>Schuitemaker, Hanneke</au><au>Van Hoof, Johan</au><au>Struyf, Frank</au><au>Douoguih, Macaya</au><aucorp>ENSEMBLE Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-06-10</date><risdate>2021</risdate><volume>384</volume><issue>23</issue><spage>2187</spage><epage>2201</epage><pages>2187-2201</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–critical Covid-19 and 85% against severe–critical Covid-19. Efficacy against the variant first identified in South Africa was 64% against moderate disease and 82% against severe–critical disease.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>33882225</pmid><doi>10.1056/NEJMoa2101544</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-2179-2436</orcidid><orcidid>https://orcid.org/0000-0001-8563-2266</orcidid><orcidid>https://orcid.org/0000-0003-4649-1477</orcidid><orcidid>https://orcid.org/0000-0001-9988-0260</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-06, Vol.384 (23), p.2187-2201 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8220996 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Ad26COVS1 Adolescent Adult Adverse events Age Aged Asymptomatic Diseases - epidemiology Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - mortality COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Disease transmission Double-Blind Method FDA approval Female Hospitalization - statistics & numerical data Humans Hypotheses Immunogenicity, Vaccine Incidence Infections Male Middle Aged Original Pandemics Patient Acuity Placebos Population Proportional Hazards Models Protein structure Protocol R&D Research & development Safety Severe acute respiratory syndrome coronavirus 2 Spike protein Vaccine efficacy Vaccines Young Adult |
| title | Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T14%3A12%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Single-Dose%20Ad26.COV2.S%20Vaccine%20against%20Covid-19&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Sadoff,%20Jerald&rft.aucorp=ENSEMBLE%20Study%20Group&rft.date=2021-06-10&rft.volume=384&rft.issue=23&rft.spage=2187&rft.epage=2201&rft.pages=2187-2201&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2101544&rft_dat=%3Cproquest_pubme%3E2539546944%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2539546944&rft_id=info:pmid/33882225&rfr_iscdi=true |